| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| N Froger, A M Gardier, R Moratalla, I Alberti, I Lena, C Boni, C De Felipe, N M Rupniak, S P Hunt, C Jacquot, M Hamon, L Lanfume. 5-hydroxytryptamine (5-HT)1A autoreceptor adaptive changes in substance P (neurokinin 1) receptor knock-out mice mimic antidepressant-induced desensitization. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 21. issue 20. 2001-11-01. PMID:11588191. |
on the other hand, cortical 5-ht overflow caused by systemic injection of the ssri paroxetine was four- to sixfold higher in freely moving nk1-/- mutants than in wild-type nk1+/+ mice. |
2001-11-01 |
2023-08-12 |
mouse |
| K Tsuboi, M Masuk. [Panic disorder and antidepressants]. Nihon rinsho. Japanese journal of clinical medicine. vol 59. issue 8. 2001-10-18. PMID:11519166. |
while the older tricyclic antidepressants(tcas) are efficacious in the treatment of theses anxiety disorders, recent studies with paroxetine and other selective serotonin reuptake inhibitors(ssris) have emphasized the role of serotonin in the aetiology of these conditions. |
2001-10-18 |
2023-08-12 |
Not clear |
| M C Dulchin, M A Oquendo, K M Malone, S P Ellis, S Li, J J Man. Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 25. issue 3. 2001-10-18. PMID:11522467. |
we found evidence of increased prolactin levels that may reflect effects of paroxetine in enhancing serotonin levels. |
2001-10-18 |
2023-08-12 |
Not clear |
| M C Dulchin, M A Oquendo, K M Malone, S P Ellis, S Li, J J Man. Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 25. issue 3. 2001-10-18. PMID:11522467. |
acute release of serotonin as measured by the prolactin response to fenfluramine is not altered by paroxetine treatment. |
2001-10-18 |
2023-08-12 |
Not clear |
| E D O'Loinsigh, G Boland, J P Kelly, K M O'Boyl. Behavioural, hyperthermic and neurotoxic effects of 3,4-methylenedioxymethamphetamine analogues in the Wistar rat. Progress in neuro-psychopharmacology & biological psychiatry. vol 25. issue 3. 2001-10-11. PMID:11371001. |
after repeated dosing (8 x 20 mg/kg, i.p., twice daily for 4 days), mdma > mdea >> mdba > or = saline at decreasing forebrain [3h]paroxetine binding levels and concentrations of 5-ht and 5-hiaa at 14 days post-treatment. |
2001-10-11 |
2023-08-12 |
rat |
| M R Goldberg, R C Lowry, D G Musson, K L Birk, A Fisher, M E De Puy, C R Shadl. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. Journal of clinical pharmacology. vol 39. issue 2. 2001-10-11. PMID:11563413. |
this study examined the clinical and pharmacolinetic interaction between rizatriptan and the selective serotonin reuptake inhibitor, paroxetine. |
2001-10-11 |
2023-08-12 |
human |
| D Marazziti, S Baroni, A Rossi, I Masala, G Giannaccini, V Gori, A Lucacchini, G B Cassan. Pharmacological characterization of the serotonin transporter in young and elderly subjects. Neuropsychobiology. vol 44. issue 2. 2001-10-04. PMID:11490175. |
the potency of some tricyclics (imipramine and clomipramine) and selective 5-ht reuptake inhibitors (fluoxetine, paroxetine, and citalopram) in displacing the [(3)h]paroxetine binding to platelet membranes was measured in young and elderly subjects of both sexes. |
2001-10-04 |
2023-08-12 |
human |
| T J Connor, M C Dennedy, A Harkin, J P Kell. Methylenedioxymethamphetamine-induced suppression of interleukin-1beta and tumour necrosis factor-alpha is not mediated by serotonin. European journal of pharmacology. vol 418. issue 1-2. 2001-09-27. PMID:11334877. |
we examined the effect of pretreatment with the selective serotonin reuptake inhibitor paroxetine, and the tryptophan hydroxylase inhibitor para-chlorophenylalanine on mdma-induced suppression of interleukin-1beta and tumour necrosis factor (tnf)-alpha secretion following an in vivo lipopolysaccharide challenge. |
2001-09-27 |
2023-08-12 |
rat |
| T J Connor, M C Dennedy, A Harkin, J P Kell. Methylenedioxymethamphetamine-induced suppression of interleukin-1beta and tumour necrosis factor-alpha is not mediated by serotonin. European journal of pharmacology. vol 418. issue 1-2. 2001-09-27. PMID:11334877. |
although paroxetine blocked mdma-induced serotonin depletion in the cortex and hypothalamus, it failed to alter the suppressive effect of mdma on lipopolysaccharide-induced tnf-alpha secretion. |
2001-09-27 |
2023-08-12 |
rat |
| M Odeh, I Misselevech, J H Boss, A Olive. Severe hepatotoxicity with jaundice associated with paroxetine. The American journal of gastroenterology. vol 96. issue 8. 2001-09-20. PMID:11513198. |
hepatotoxicity due to paroxetine, a selective serotonin reuptake inhibitor, is very rare, and to the best of our knowledge, only five cases of liver injury in association with paroxetine have previously been reported in the medical literature. |
2001-09-20 |
2023-08-12 |
Not clear |
| A C Wihlbäck, I Sundström-Poromaa, P Allard, T Mjörndal, O Spigset, T Bäckströ. Influence of postmenopausal hormone replacement therapy on platelet serotonin uptake site and serotonin 2A receptor binding. Obstetrics and gynecology. vol 98. issue 3. 2001-09-20. PMID:11530128. |
to examine whether binding of [3h]paroxetine to the platelet serotonin transporter or binding of [3h]lysergic acid diethylamide (lsd) to the platelet 5-ht(2a) receptor are influenced by postmenopausal estrogen/progestogen treatment. |
2001-09-20 |
2023-08-12 |
Not clear |
| G K Isbister, A Dawson, I M Whyte, F H Prior, C Clancy, A J Smit. Neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? Archives of disease in childhood. Fetal and neonatal edition. vol 85. issue 2. 2001-09-20. PMID:11561552. |
neonatal paroxetine withdrawal syndrome or actually serotonin syndrome? |
2001-09-20 |
2023-08-12 |
Not clear |
| J Bolton, G J Moore, S MacMillan, C M Stewart, D R Rosenber. Case study: caudate glutamatergic changes with paroxetine persist after medication discontinuation in pediatric OCD. Journal of the American Academy of Child and Adolescent Psychiatry. vol 40. issue 8. 2001-09-13. PMID:11501689. |
in this report, ocd symptoms improved markedly in an 8-year-old girl treated for 14 months with the selective serotonin reuptake inhibitor paroxetine (titrated from 10 to 40 mg/day). |
2001-09-13 |
2023-08-12 |
Not clear |
| A J Mayorga, A Dalvi, M E Page, S Zimov-Levinson, R Hen, I Luck. Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice. The Journal of pharmacology and experimental therapeutics. vol 298. issue 3. 2001-09-13. PMID:11504807. |
in the current study, the effects of two types of antidepressant drugs, the selective serotonin reuptake inhibitors fluoxetine and paroxetine and the selective norepinephrine reuptake inhibitor desipramine, were examined in 5-hydroxytryptamine (5-ht)(1a) and 5-ht(1b) receptor mutant mice using the tail suspension test (tst). |
2001-09-13 |
2023-08-12 |
mouse |
| M Bixo, P Allard, T Bäckström, T Mjörndal, S Nyberg, O Spigset, I Sundström-Poroma. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology. vol 26. issue 6. 2001-08-23. PMID:11403977. |
binding of [3h]paroxetine to serotonin uptake sites and of [3h]lysergic acid diethylamide to 5-ht2a receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. |
2001-08-23 |
2023-08-12 |
Not clear |
| M Bixo, P Allard, T Bäckström, T Mjörndal, S Nyberg, O Spigset, I Sundström-Poroma. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment. Psychoneuroendocrinology. vol 26. issue 6. 2001-08-23. PMID:11403977. |
in the present study, binding of [3h]paroxetine to platelet serotonin uptake sites and binding of [3h]lysergic acid diethylamide ([3h]lsd) to platelet serotonin (5-ht)2a receptors were studied in patients with pmdd treated with a low dose of a gonadotropin releasing hormone (gnrh) agonist (buserelin) or placebo and compared to controls. |
2001-08-23 |
2023-08-12 |
Not clear |
| A M Gardier, A C Trillat, I Malagié, D David, M Hascoët, M C Colombel, P Jolliet, C Jacquot, R Hen, M Bouri. [5-HT1B serotonin receptors and antidepressant effects of selective serotonin reuptake inhibitors ]. Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie. vol 324. issue 5. 2001-08-02. PMID:11417564. |
however, in the ventral hippocampus, paroxetine at the two doses studied induced a larger increase in [5-ht]ext in knockout than in wild-type mice. |
2001-08-02 |
2023-08-12 |
mouse |
| A M Gardier, A C Trillat, I Malagié, D David, M Hascoët, M C Colombel, P Jolliet, C Jacquot, R Hen, M Bouri. [5-HT1B serotonin receptors and antidepressant effects of selective serotonin reuptake inhibitors ]. Comptes rendus de l'Academie des sciences. Serie III, Sciences de la vie. vol 324. issue 5. 2001-08-02. PMID:11417564. |
in addition, either the absence of the 5-ht1b receptor or its blockade with the mixed 5-ht1b/1d receptor antagonist, gr 127935, potentiates the effect of a single administration of paroxetine on [5-ht]ext more in the ventral hippocampus than in the frontal cortex. |
2001-08-02 |
2023-08-12 |
mouse |
| H Weicker, H K Strüde. Influence of exercise on serotonergic neuromodulation in the brain. Amino acids. vol 20. issue 1. 2001-07-26. PMID:11310929. |
acute paroxetine (selective serotonin (5-ht) reuptake inhibitor) administration to endurance athletes, who performed a cycle ergometer test to exhaustion at moderate intensity, reduced time to exhaustion and post exercise cognitive performance in comparison to trials with placebo or bcaa administration. |
2001-07-26 |
2023-08-12 |
Not clear |
| M Bourin, P Chue, Y Guillo. Paroxetine: a review. CNS drug reviews. vol 7. issue 1. 2001-07-26. PMID:11420571. |
paroxetine is a potent and selective serotonin reuptake inhibitor (ssri) with currently approved indications for the treatment of depression, obsessive-compulsive disorder, panic disorder and social phobia. |
2001-07-26 |
2023-08-12 |
Not clear |